Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Short Interest Update

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Get Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 1,490,000 shares, a decline of 24.4% from the August 15th total of 1,970,000 shares. Approximately 3.6% of the shares of the company are sold short. Based on an average trading volume of 1,600,000 shares, the short-interest ratio is currently 0.9 days.

Amylyx Pharmaceuticals Trading Up 5.2 %

Shares of Amylyx Pharmaceuticals stock traded up $0.13 on Friday, reaching $2.62. 843,141 shares of the company were exchanged, compared to its average volume of 2,128,136. The stock has a fifty day moving average price of $2.12 and a 200-day moving average price of $2.84. The firm has a market capitalization of $178.18 million, a price-to-earnings ratio of -2.45 and a beta of -0.62. Amylyx Pharmaceuticals has a fifty-two week low of $1.58 and a fifty-two week high of $20.44.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.35). The company had revenue of ($1.02) million for the quarter, compared to analyst estimates of $18.83 million. Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. During the same period last year, the firm earned $0.31 earnings per share. On average, equities analysts anticipate that Amylyx Pharmaceuticals will post -2.27 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. The Goldman Sachs Group boosted their price objective on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a "neutral" rating in a research note on Friday, July 12th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a research note on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $17.60.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, Director George M. Milne, Jr. bought 100,000 shares of the business's stock in a transaction on Tuesday, September 3rd. The shares were purchased at an average price of $2.20 per share, with a total value of $220,000.00. Following the purchase, the director now directly owns 858,571 shares of the company's stock, valued at $1,888,856.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 11.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of AMLX. Vanguard Group Inc. grew its holdings in shares of Amylyx Pharmaceuticals by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,348,139 shares of the company's stock valued at $15,189,000 after buying an additional 72,573 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Amylyx Pharmaceuticals by 2,768.0% during the second quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company's stock valued at $6,348,000 after buying an additional 3,224,454 shares in the last quarter. Almitas Capital LLC purchased a new position in shares of Amylyx Pharmaceuticals during the second quarter valued at $3,617,000. Franklin Resources Inc. grew its holdings in shares of Amylyx Pharmaceuticals by 114.4% during the fourth quarter. Franklin Resources Inc. now owns 1,325,001 shares of the company's stock valued at $19,504,000 after buying an additional 707,134 shares in the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in Amylyx Pharmaceuticals by 5.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,256,861 shares of the company's stock valued at $18,501,000 after purchasing an additional 69,733 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.